Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Re-vaccination for TB Prophylaxis in Prisons
NCT05541952Phase 4Withdrawn
- Sponsor
- Universidade Federal de Mato Grosso
- Start
- Aug 2020
- Primary completion
- Aug 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bcg vaccine in Tuberculosis (TB) (2 arms), sponsored by Universidade Federal de Mato Grosso. Primary endpoint: Incidence of Latent Tuberculosis Infection at 6 months. Planned start Aug 2020; status: withdrawn.
02
Drugs
bcg vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05541952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541952.